OS Therapies Incorporated
OSTX
$1.77
$0.031.61%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -23.69% | 52.25% | 154.59% | 510.44% | 1,274.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.38% | 304.12% | 182.25% | 520.51% | 693.32% |
| Operating Income | -103.38% | -304.12% | -182.25% | -520.51% | -693.32% |
| Income Before Tax | -168.17% | -350.01% | -139.27% | -191.27% | -165.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -168.17% | -350.01% | -139.27% | -191.27% | -165.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -168.17% | -350.01% | -139.27% | -191.27% | -165.72% |
| EBIT | -103.38% | -304.12% | -182.25% | -520.51% | -693.32% |
| EBITDA | -100.91% | -300.10% | -177.13% | -506.62% | -694.09% |
| EPS Basic | -47.37% | 99.35% | -19.02% | 30.54% | 26.66% |
| Normalized Basic EPS | -47.37% | 99.35% | -19.03% | 30.52% | 25.10% |
| EPS Diluted | -47.37% | 99.35% | -19.02% | 30.54% | 26.66% |
| Normalized Diluted EPS | -47.37% | 99.35% | -19.03% | 30.52% | 25.10% |
| Average Basic Shares Outstanding | 82.00% | 68,893.66% | 101.02% | 319.20% | 254.69% |
| Average Diluted Shares Outstanding | 82.00% | 68,893.66% | 101.02% | 319.20% | 254.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |